Antibody-drug conjugates for first- and second-line treatment of metastatic HER2‑negative and triple‑negative breast cancer
Official title: ENCORE: Multicenter ProspectivE Registry of Sequential ANtibody Drug COnjugates (ADCs) in HER2 Negative Metastatic BREast Cancer (MBC)
Run by University of California, San Francisco · NCT06774027 · Data updated 2026-11-12
This prospective registry will collect real-world data to see how FDA-approved antibody-drug conjugates work as first- or second-line treatments for adults with metastatic HER2‑negative or triple-negative breast cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 3 sites (San Francisco, California and 2 other locations) |
| Status | Recruiting |
| Started | October 8, 2025 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2030 |
| Registry record updated | October 16, 2026 |
| Trial ID | NCT06774027 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with histologically documented metastatic HR+/HER2‑ or metastatic triple‑negative breast cancer who plan to start an FDA-approved ADC as their first or second ADC, can provide informed consent, and are willing to provide tissue and blood samples are ideal candidates.
✕Probably not a fit
Patients who are not receiving an FDA-approved ADC, who have received prior experimental ADCs, who have a very limited life expectancy (under three months), or who decline tissue/blood sampling are unlikely to benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, multi-site observational registry enrolling adults with metastatic HR+/HER2‑ or triple‑negative breast cancer who are starting an FDA-approved antibody-drug conjugate (ADC) as their first or second ADC under routine care. Researchers will perform medical chart reviews, collect biospecimens (archival tissue and serial blood draws), and record safety and patient-reported outcomes while patients receive ADC1 and/or ADC2. Primary endpoints include real-world progression-free survival for first- and second-line ADCs, with secondary endpoints of duration of response, best overall response, disease control rate, overall survival, and safety by chart review. Exploratory analyses will look for correlative biomarkers such as ctDNA and circulating tumor cells and will follow patients for survival every 12 weeks for up to two years after the last ADC dose.
Why it matters
Potential benefit: If successful, this registry could help doctors understand how ADCs perform in routine practice and guide treatment and monitoring decisions for patients outside clinical trials.
How similar studies have gone: Randomized phase III trials of specific ADCs have shown meaningful improvements in progression-free and overall survival in mTNBC and HR+/HER2‑ metastatic breast cancer, though prospective real-world registries like this are less common.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male or female patients aged 18 years or greater with ability to provide written informed consent for this prospective registry study. 2. Estimated life expectancy of at least at 3 months per investigator assessment. 3. Willingness to provide an archival tissue sample and blood samples (20cc research blood collection at several timepoints) for research purposes. 4. Cohort-specific enrollment criteria: * Cohort 1: Histologically documented HR+/HER2- MBC with plan to start an FDA-approved ADC as their first ADC per standard of care (SOC). * Cohort 2: Histologically documented metastatic TNBC with plan to start an FDA-approved ADC as their first ADC per standard of care * Cohort 3: Histologically documented HR+/HER2- MBC with plan to start an FDA-approved ADC as their second ADC per standard of care (ADC1 should be an approved ADC administered per SOC or as monotherapy in a clinical trial; no prior experimental ADCs allowed). Clinical data from the first ADC must be available for retrospective review. * Cohort 4: Histologically documented metastatic TNBC with plan to start an FDA-approved ADC as their second ADC per standard of care (ADC1 should be an approved ADC administered per standard of care or as monotherapy in a clinical trial; no prior experimental ADCs allowed). Clinical data from the first ADC must be available for retrospective review. * Measurable disease is not required for any cohort. Exclusion Criteria: 1. Prior receipt of an experimental ADC in the metastatic setting. Of note, patients who received an FDA-approved ADC as their first ADC (as monotherapy, not in combination) can participate in cohorts 3 or 4 prior to starting their second FDA-approved ADC per standard of care. Of note, for all cohorts, experimental therapies are not allowed as intervening therapies after starting ADC1. If a patient enrolls on a clinical trial of an experimental therapy after ADC1, they will be taken off study. 2. Current participation in a clinical trial with an ADC. 3. Contraindication to research phlebotomy to collect \~20cc blood at each research blood draw timepoint.
Where it's running
-
University of California, San Francisco
San Francisco, California, United States Recruiting -
Montefiore Einstein Comprehensive Cancer Center
The Bronx, New York, United States Recruiting -
Duke Cancer Institute
Durham, North Carolina, United States Recruiting
Study contacts
- Principal investigator: Laura Huppert, MD,BA — University of California, San Francisco
- Study coordinator: Amy Langdon
- Email: Amy.Deluca@ucsf.edu
- Phone: (415) 353-7288
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Testing Abemaciclib with Radiation Therapy for Metastatic Breast Cancer
This study is testing different doses of the drug abemaciclib in people with metastatic breast cancer who are also getting hormone therapy and radiation to see if it helps them better manage their symptoms.
-
Measuring a biomarker for breast cancer treatment effectiveness
This study is testing if measuring a specific biomarker can help doctors understand how well hormone treatments are working for people with advanced breast cancer.
-
Datopotamab deruxtecan for treating breast cancer that has spread to the brain
This study is testing a new drug called datopotamab deruxtecan to see if it can help people with HER2-negative breast cancer that has spread to the brain.
-
PRT13722 in advanced HR+/HER2- breast cancer
This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.
-
Pre-surgery hormone therapy to lower positive margins in lobular breast cancer
This Phase 2 trial tests whether giving endocrine (hormone) therapy before breast-conserving surgery can reduce the chance of cancer at the edges of the removed tissue in postmenopausal people with ER+/HER2- invasive lobular breast cancer.
-
Capivasertib plus endocrine therapy for HR+/HER2- advanced breast cancer after progression on endocrine treatment
This trial will test whether adding capivasertib to standard endocrine therapy helps adults with HR+/HER2- advanced or metastatic breast cancer who progressed on prior endocrine treatment stay on treatment longer and maintain quality of life.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.